Chinese pharma giant Hansoh just swallowed a $21 million Nasdaq shell company, stuffed it with $320 million in cash, and loaded in an oral pill that could disrupt the blockbuster IL-23 market. It's the boldest reverse-merger play in biotech this year.
A $21 Million Shell Just Became a $320 Million Drug Company
NextCure was, by most measures, a company running out of reasons to exist. The Maryland-based biotech had been public since 2019, raised roughly $446 million over its lifetime, and never sold a single product. It was, in the gentlest possible terms, a Nasdaq-listed shell waiting for someone to move in.
Someone just did.
On July 14, 2026, Chinese pharma giant Hansoh Pharmaceutical announced that its newly created U.S. subsidiary, Avere Therapeutics, would combine with NextCure in an all-stock reverse merger. The deal comes packaged with $320 million in fresh financing and an exclusive license to develop Hansoh's oral IL-23 drug (a pill that targets a protein driving inflammatory diseases like psoriasis) outside of China.
When the dust settles, NextCure's existing shareholders will own roughly 1.2% of the combined company. Avere's backers get the other 98.8%. If that sounds less like a merger and more like Avere buying a parking spot on Nasdaq, well, that's exactly what it is.
The Trojan Horse Strategy
Reverse mergers aren't new. They're the corporate equivalent of buying a fixer-upper instead of building from scratch: you skip the long, expensive IPO process and move into an already-listed company. The public shell provides the Nasdaq address; you bring the furniture.
What is notable is how Chinese biotech companies have turned this into a repeating playbook. In November 2024, Cullgen announced a reverse merger with Nasdaq-listed Pulmatrix, with Cullgen shareholders set to own 96.4% of the combined entity. A month later, Chuangxiang Biotech struck a similar deal with Ikena Oncology, bundled with $75 million in financing.
Hansoh's version is the biggest and boldest yet. The $320 million raise (from institutional investors including Fairmount and Hansoh itself) dwarfs anything the earlier deals pulled in. And while the structure might look like financial plumbing, the strategic logic is straightforward: Hansoh wants its drugs in Western markets, and the fastest route runs through a Nasdaq ticker symbol.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
What's Actually in the Box
The crown jewel of this deal is AVR-001, known internally at Hansoh as HS-20118. It's an oral cyclic peptide that blocks the IL-23 receptor, a protein involved in driving autoimmune inflammation. If that sounds familiar, it should: injectable IL-23 blockers like Skyrizi and Tremfya are already blockbusters in psoriasis and inflammatory bowel disease. The twist is that AVR-001 is designed to be taken as a once-weekly pill.
Swapping an injection for a pill is a big deal in immunology. Patients overwhelmingly prefer oral medications, and any company that cracks the oral IL-23 code could capture enormous market share. Think of it like the shift from DVD players to streaming: the content is similar, but the delivery method changes everything.
Hansoh already has Phase 1b data from China supporting the drug's efficacy in moderate-to-severe plaque psoriasis. A U.S. IND (the green light from the FDA to start clinical trials) is already open. Avere plans to kick off a Phase 2b psoriasis study in early 2027, with results expected in the first half of 2028. A Phase 3 psoriasis trial and a Phase 2b ulcerative colitis study are also on the roadmap.
None of this is cheap, which is why the $320 million matters so much.
Follow the Money
The financial architecture of this deal has more layers than a wedding cake. Let's walk through it.
Hansoh's payday: The licensing agreement pays Hansoh $120 million upfront for the ex-China rights to AVR-001. On top of that, Hansoh could earn up to $2.18 billion in development and sales milestones, plus tiered royalties ranging from mid-single-digit to low-double-digit percentages on future sales. Hansoh keeps all rights in Greater China.
The financing: Avere raised approximately $320 million through a private placement, structured as a mix of equity and pre-funded warrants. This capital is earmarked for the clinical development of AVR-001.
Convertible notes: Avere also has $251 million in convertible notes (plus interest) that will convert into stock when the merger closes.
NextCure shareholders: They get their sliver of equity in the combined company, plus Contingent Value Rights (CVRs) entitling them to 90% of net proceeds from any monetization of NextCure's old pipeline assets over a two-year window. It's essentially a lottery ticket on programs the market had already priced at near-zero.
The combined company will trade under the ticker AVRX and be led by Dr. Andrew Cheng, Avere's current CEO.
Hansoh's Bigger Game
This deal doesn't exist in a vacuum. Hansoh has been on a licensing tear that would make a Hollywood agent jealous.
Since late 2023, the company has signed out-licensing agreements with GSK, Merck, Regeneron, Roche, and Glenmark, covering assets in oncology and metabolism. The aggregate milestone potential across those deals approaches $9 billion. Each one follows a similar template: Hansoh develops the drug in China, then hands off ex-China rights to a global partner with the infrastructure to run Western clinical trials and commercialize in the U.S. and Europe.
The Avere deal is a twist on that formula. Instead of licensing to an established pharma company, Hansoh created its own U.S. entity, funded it, and gave it a public listing. It's the difference between renting out your house and building a hotel. The upside is bigger, and so is the control.
Hansoh also maintains a research center in Maryland, giving it a permanent footprint for interacting with the FDA and U.S. clinical networks. The company has been exporting active pharmaceutical ingredients to the U.S. since 2003 and already has multiple finished products on the American market.
Why This Matters Beyond One Deal
The reverse-merger route for Chinese biotech carries historical baggage. The last big wave, in the late 2000s and early 2010s, ended in a string of fraud allegations, short-seller attacks, and stock collapses that made investors deeply skeptical of the model.
This time feels different, at least structurally. Avere isn't a mystery company borrowing a ticker; it's backed by a major Chinese pharma group with partnerships with five of the world's largest drugmakers. The $320 million raise from institutional investors provides a layer of due diligence that the earlier wave often lacked. And the asset itself (an oral IL-23 inhibitor) targets a validated, multi-billion-dollar market where unmet need is real.
But "different" doesn't mean "guaranteed." The merger still needs NextCure shareholder approval, SEC sign-off on the registration statement, and Nasdaq's blessing. Closing is targeted for Q3 2026. And even if everything goes smoothly on the corporate side, AVR-001 still has to prove itself in U.S. trials against a competitive field of oral and injectable IL-23 therapies.
The Bottom Line
Hansoh just built itself a Nasdaq-listed vehicle, loaded it with $320 million in cash and a potentially best-in-class oral drug, and pointed it at one of immunology's biggest markets. NextCure's shareholders, meanwhile, went from holding a stock worth less than a cup of coffee to owning a tiny piece of something much more interesting.
Whether this becomes the template for how Chinese innovation reaches American patients (or just a well-funded experiment) depends on what happens in the clinic. The corporate engineering is impressive. Now AVR-001 has to deliver the science to match.
Clinical & Regulatory5 min read
Wegovy Just Became a Liver Drug.
India just approved Wegovy for fatty liver disease, making it the second country to clear a GLP-1 drug for MASH. With nearly 40% of Indian adults affected by fatty liver and zero prior approved treatments, Novo Nordisk's latest label expansion could reshape both the Indian pharma market and the global MASH treatment landscape.
